Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Shares Outstanding (Diluted Average) (2020 - 2024)

Immuneering has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $29.6 million for Q3 2024.

  • Quarterly results put Shares Outstanding (Diluted Average) at $29.6 million for Q3 2024, up 5.31% from a year ago — trailing twelve months through Sep 2024 was $29.6 million (up 5.31% YoY), and the annual figure for FY2023 was $28.4 million, up 7.69%.
  • Shares Outstanding (Diluted Average) for Q3 2024 was $29.6 million at Immuneering, roughly flat from $29.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for IMRX hit a ceiling of $29.7 million in Q2 2024 and a floor of $5.0 million in Q2 2020.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $26.4 million (2022), compared with a mean of $20.1 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 0.09% in 2021 and later soared 432.57% in 2022.
  • Immuneering's Shares Outstanding (Diluted Average) stood at $5.0 million in 2020, then skyrocketed by 175.0% to $13.6 million in 2021, then surged by 93.84% to $26.4 million in 2022, then grew by 7.69% to $28.4 million in 2023, then rose by 4.24% to $29.6 million in 2024.
  • The last three reported values for Shares Outstanding (Diluted Average) were $29.6 million (Q3 2024), $29.7 million (Q2 2024), and $29.4 million (Q1 2024) per Business Quant data.